Dexcel Pharma Improves Visibility and Agility with Infor
Infor, a leading provider of business application software serving more than 73,000 customers, today announced that Israeli pharmaceutical manufacturer Dexcel Pharma, globally implemented Infor M3. Delivered on time and budget by Infor partner Intentia Israel, the Enterprise Resource Planning (ERP) application will help improve decision making and visibility, enabling Dexcel Pharma to achieve more uniformity across group companies in the UK, Germany and Israel.
Dexcel Pharma is a private, international pharmaceutical company, with over 1,000 employees. It is the second largest Israeli pharmaceutical manufacturer, supplying 25 percent of the branded and generic pharmaceuticals sold in Israel.
Infor M3 will help deliver consistency and facilitate transparency across the information generated by Dexcel's sales and distribution operations in Europe and the corporate headquarters in Israel, whilst supporting Dexcel's adherence to high standards of compliance required in the pharmaceutical industry.
Key to the success of the project was the smooth integration of sales, purchasing, production, distribution, and finance processes, specifically Infor M3's ability to support German-specific SEPA requirements. An automated warehouse and inventory module terminals have also been integrated, while the development of specific modules to synchronize all sites means that Dexcel is able to exercise greater agility through having consistent information.
"As a global pharmaceutical leader, we take the meticulous compliance demands of such a project very seriously," said Miri Peleg, Director of Information Systems at Dexcel Pharma. "In addition we wanted a system that was functionally very rich. Infor M3 was an obvious choice as it delivered functionality and facilitated compliance."
"Global pharmaceutical manufacturing is a complex and fast moving industry," said Alain Raflé, regional channel manager for Israel, Infor. "The systems that underpin success must support regulatory compliance, and deliver operational agility and speed. Infor M3 is designed to do exactly that."
Uzi Yaari, CEO of Intentia Advanced Solutions said, "Using our unique rapid implementation methodology we were not only able to implement the solution quickly but also streamline the work processes within Dexcel. The regulations and advanced validation procedures required by the international pharmaceutical industry, demand high-quality implementation schedules, but these must be part of an implementation timeframe and budget that is commercially viable."
About Intentia Israel
Intentia Israel was established in 1996 and specializes in industrial computing for manufacturing organizations. Intentia Israel is the exclusive representative in Israel for the Infor M3 ERP application.
Keep Current on Infor:
- Subscribe to the Infor RSS Feed
- Follow Infor on Twitter
- Connect with Infor on LinkedIn
- Like Infor on Facebook
- View Infor videos on YouTube
Infor is fundamentally changing the way information is published and consumed in the enterprise, helping 73,000 customers in more than 200 countries and territories improve operations, drive growth, and quickly adapt to changes in business demands. Infor offers deep industry-specific applications and suites, engineered for speed, and with an innovative user experience design that is simple, transparent, and elegant. Infor provides flexible deployment options that give customers a choice to run their businesses in the cloud, on-premises, or both. To learn more about Infor, please visit www.infor.com.
Infor customers include:
- 19 of the top 20 aerospace companies
- 10 of the top 10 high tech companies
- 10 of the top 10 pharmaceutical companies
- 22 of the 25 largest US healthcare delivery networks
- 16 of the 20 largest US cities
- 20 of the top 20 automotive suppliers
- 17 of the top 20 industrial distributors
- 16 of the top 20 global retailers
- 4 of the top 5 brewers
- 21 of the top 30 global banks
- 6 of the top 10 global luxury brands
- Press Releases
- North America
We'll be in touch.